

PKA I α reg (C-14): sc-18800

BACKGROUND

The second messenger cyclic AMP (cAMP) mediates diverse cellular responses to external signals such as proliferation, ion transport, regulation of metabolism and gene transcription by activation of the cAMP-dependent protein kinase (cAPK or PKA). Activation of PKA occurs when cAMP binds to the two regulatory subunits of the tetrameric PKA holoenzyme, resulting in release of active catalytic subunits. Four different PKA regulatory subunits have been identified, designated I α , I β , II α and II β . The PKA I α reg protein is a tissue-specific extinguisher that downregulates the expression of seven liver genes in hepatoma x fibroblast hybrids. Functional null mutations in the gene that codes for PKA I α reg cause Carney complex (CNC). CNC is an autosomal dominant multiple neoplasia syndrome. CNC is associated with a variety of characterized symptoms such as cardiac and other myxomas, spotty skin pigmentation, endocrine tumors and psammomatous melanotic schwannomas.

CHROMOSOMAL LOCATION

Genetic locus: PRKAR1A (human) mapping to 17q24.2; Prkar1a (mouse) mapping to 11 E1.

SOURCE

PKA I α reg (C-14) is an affinity purified goat polyclonal antibody raised against a peptide mapping within an internal region of PKA I α reg of human origin.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-18800 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

PKA I α reg (C-14) is recommended for detection of PKA I α reg of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 μ g per 100-500 μ g of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

PKA I α reg (C-14) is also recommended for detection of PKA I α reg in additional species, including canine and avian.

Suitable for use as control antibody for PKA I α reg siRNA (h): sc-39162, PKA I α reg siRNA (m): sc-39163, PKA I α reg shRNA Plasmid (h): sc-39162-SH, PKA I α reg shRNA Plasmid (m): sc-39163-SH, PKA I α reg shRNA (h) Lentiviral Particles: sc-39162-V and PKA I α reg shRNA (m) Lentiviral Particles: sc-39163-V.

Molecular Weight of PKA I α reg: 43 kDa.

Positive Controls: SW-13 cell lysate: sc-24778 or rat cerebellum extract: sc-2398.


RESEARCH USE

For research use only, not for use in diagnostic procedures.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

DATA



PKA I α reg (C-14): sc-18800. Western blot analysis of PKA I α reg expression in SW-13 whole cell lysate.

SELECT PRODUCT CITATIONS

- Griffin, K.J., et al. 2004. Down-regulation of regulatory subunit type 1A of protein kinase A leads to endocrine and other tumors. *Cancer Res.* 64: 8811-8815.
- Fernández, S., et al. 2008. Modulation by Insulin-like growth factor I of the phosphatase PTEN in astrocytes. *Biochim. Biophys. Acta* 1783: 803-812.
- Aye, T.T., et al. 2009. Selectivity in enrichment of cAMP-dependent protein kinase regulatory subunits type I and type II and their interactors using modified cAMP affinity resins. *Mol. Cell. Proteomics* 8: 1016-1028.
- Waldkirch, E., et al. 2010. Expression of cAMP-dependent protein kinase isoforms in the human prostate: functional significance and relation to PDE4. *Urology* 76: 515.e8-515.e14.
- Fernandez, S., et al. 2014. A phosphatase-independent gain-of-function mutation in PTEN triggers aberrant cell growth in astrocytes through an autocrine IGF-1 loop. *Oncogene* 33: 4114-4122.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.



Try **PKA I α / β reg (B-6): sc-271125** or **PKA I α reg (20): sc-136231**, our highly recommended monoclonal alternatives to PKA I α reg (C-14).